BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 17499324)

  • 1. Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: a progress report.
    Clewell HJ; Thomas RS; Gentry PR; Crump KS; Kenyon EM; El-Masri HA; Yager JW
    Toxicol Appl Pharmacol; 2007 Aug; 222(3):388-98. PubMed ID: 17499324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic-induced carcinogenesis--oxidative stress as a possible mode of action and future research needs for more biologically based risk assessment.
    Kitchin KT; Conolly R
    Chem Res Toxicol; 2010 Feb; 23(2):327-35. PubMed ID: 20035570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically based pharmacokinetic modeling of arsenic in the mouse.
    Gentry PR; Covington TR; Mann S; Shipp AM; Yager JW; Clewell HJ
    J Toxicol Environ Health A; 2004 Jan; 67(1):43-71. PubMed ID: 14668111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How can biologically-based modeling of arsenic kinetics and dynamics inform the risk assessment process? - A workshop review.
    Kenyon EM; Klimecki WT; El-Masri H; Conolly RB; Clewell HJ; Beck BD
    Toxicol Appl Pharmacol; 2008 Nov; 232(3):359-68. PubMed ID: 18687352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk assessment of arsenic-induced internal cancer at long-term low dose exposure.
    Liao CM; Shen HH; Chen CL; Hsu LI; Lin TL; Chen SC; Chen CJ
    J Hazard Mater; 2009 Jun; 165(1-3):652-63. PubMed ID: 19062162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic, mode of action at biologically plausible low doses: what are the implications for low dose cancer risk?
    Snow ET; Sykora P; Durham TR; Klein CB
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):557-64. PubMed ID: 15996700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of mode of action data to inform a dose-response assessment for bladder cancer following exposure to inorganic arsenic.
    Gentry PR; Yager JW; Clewell RA; Clewell HJ
    Toxicol In Vitro; 2014 Oct; 28(7):1196-205. PubMed ID: 24937311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic-induced bladder cancer in an animal model.
    Cohen SM; Ohnishi T; Arnold LL; Le XC
    Toxicol Appl Pharmacol; 2007 Aug; 222(3):258-63. PubMed ID: 17109909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in C57BL6 mice following subchronic exposure to arsenate in drinking water.
    Kenyon EM; Hughes MF; Adair BM; Highfill JH; Crecelius EA; Clewell HJ; Yager JW
    Toxicol Appl Pharmacol; 2008 Nov; 232(3):448-55. PubMed ID: 18706920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the carcinogenicity of inorganic arsenic.
    Cohen SM; Arnold LL; Beck BD; Lewis AS; Eldan M
    Crit Rev Toxicol; 2013 Oct; 43(9):711-52. PubMed ID: 24040994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer risk assessment for 1,3-butadiene: data integration opportunities.
    Preston RJ
    Chem Biol Interact; 2007 Mar; 166(1-3):150-5. PubMed ID: 16647696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of genomic dose-response information on arsenic to inform key events in a mode of action for carcinogenicity.
    Gentry PR; McDonald TB; Sullivan DE; Shipp AM; Yager JW; Clewell HJ
    Environ Mol Mutagen; 2010 Jan; 51(1):1-14. PubMed ID: 19551812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addressing nonlinearity in the exposure-response relationship for a genotoxic carcinogen: cancer potency estimates for ethylene oxide.
    Kirman CR; Sweeney LM; Teta MJ; Sielken RL; Valdez-Flores C; Albertini RJ; Gargas ML
    Risk Anal; 2004 Oct; 24(5):1165-83. PubMed ID: 15563286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research approaches to address uncertainties in the risk assessment of arsenic in drinking water.
    Hughes MF; Kenyon EM; Kitchin KT
    Toxicol Appl Pharmacol; 2007 Aug; 222(3):399-404. PubMed ID: 17379267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites.
    Kitchin KT
    Toxicol Appl Pharmacol; 2001 May; 172(3):249-61. PubMed ID: 11312654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer dose--response assessment for acrylonitrile based upon rodent brain tumor incidence: use of epidemiologic, mechanistic, and pharmacokinetic support for nonlinearity.
    Kirman CR; Gargas ML; Marsh GM; Strother DE; Klaunig JE; Collins JJ; Deskin R
    Regul Toxicol Pharmacol; 2005 Oct; 43(1):85-103. PubMed ID: 16099568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A human PBPK/PD model to assess arsenic exposure risk through farmed tilapia consumption.
    Ling MP; Liao CM
    Bull Environ Contam Toxicol; 2009 Jul; 83(1):108-14. PubMed ID: 19452117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of arsenic genotoxicity for dose response of carcinogenic effects.
    Rudel R; Slayton TM; Beck BD
    Regul Toxicol Pharmacol; 1996 Apr; 23(2):87-105. PubMed ID: 8661328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiling of responses to dimethylarsinic acid in female F344 rat urothelium.
    Sen B; Wang A; Hester SD; Robertson JL; Wolf DC
    Toxicology; 2005 Nov; 215(3):214-26. PubMed ID: 16122865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral exposure to inorganic arsenic: evaluation of its carcinogenic and non-carcinogenic effects.
    Schuhmacher-Wolz U; Dieter HH; Klein D; Schneider K
    Crit Rev Toxicol; 2009; 39(4):271-98. PubMed ID: 19235533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.